Agenus’ Post

📢 Asieris Pharmaceuticals is thrilled to share our 2023 Annual Report, highlighting a year of remarkable achievements! Our flagship drug, APL-1702, has not only succeeded in global Phase III clinical trials but also set new benchmarks in treatment efficacy. Additionally, our innovative APL-1706 has officially received NDA acceptance. A special shoutout to our Specialty Commercial Team, whose efforts have significantly bolstered our revenue streams. Dive into more on our website and follow us for more exciting updates! #AsierisPharmaceuticals #AnnualReport #ClinicalTrials #Innovation

Patient Engagement in Drug Development: The Rise of Patient-centric Approaches Discover the positive impact of active patient engagement in shaping innovative therapies and fostering mutual benefits for patients and pharmaceutical companies in our latest blog post. 👉 https://lnkd.in/dVUF5WkP #patientcentricity #patientengagement #clinicaltrials #clinicalresearch #CRO #klinischeForschung

Dive into the latest strategic move in healthcare. Novo Nordisk's acquisition of Cardior Pharmaceuticals reflects a focused approach to expanding cardiovascular therapies. Stay informed on industry advancements. #mergerandacquisition #acquisition #pharmaceutical #healthcareindustry #cardiovasculartherapy #boitech #industryinsights #newsupdate #claight #EMR #EMRhealthcare #expertmarketresearch #news

On the latest episode of Inside the Blueprint, we went behind the scenes of a company providing accessible, high-quality medications and venturing into biosimilars and proprietary medicines. Join us on Inside the Blueprint to learn more about Amneal Pharmaceuticals' journey in the pharmaceutical industry and their commitment to improving patient care: https://bit.ly/3Re6uuX #PharmaceuticalInnovation #HealthcareIndustry #Biosimilars #InsideTheBlueprint

Catch industry leader Amneal Pharmaceuticals on the latest episode of Inside the Blueprint. See how they're making significant strides in the realms of biosimilars, injectables, and proprietary medicines. #PharmaceuticalInnovation #HealthcareExcellence #Biosimilars #InsideTheBlueprint

Abbvie is arguably the poster-child for thwarting competitive pricing for high-end pharmaceuticals. Now that the company is no longer able to hold off product competition for it popular Humira drug, the number of biosimilar products is exploding...and consequently, the number of PBM's and Insurers that put biosimilars for Humira in their forumlary is growing. Net result: biosimilar competition lowers drug costs by creating competitive alternatives to which the purchases can use to leverage improved negotiations. https://lnkd.in/giyqvzHQ

ActivEyes mesotherapy : Your eyes are a perfect reflection of the beauty within your soul. 🇬🇷 Lab.Newmed Pharmaceuticals📞 2106832821 #labnewmed #labnewmedpharmaceuticals #eyes #mesotherapy #activeyes

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Mirum Pharmaceuticals, Vivet Therapeutics https://lnkd.in/gHDeS-Cq #marketanalysis #marketresearch #marketresearchreports #businessintelligence

Personalized medicines accounted for at least 25 percent of FDA-approved drugs for each of the last eight years, up from next to none 20 years ago. But in recent years, economic and political landscapes have begun to shift. At the PMC conference on Nov. 30, Randy Burkholder (PhRMA), Gabriele Allegri (The Janssen Pharmaceutical Companies of Johnson & Johnson), Sarah Hersey (Bristol Myers Squibb), Steffan Ho, MD, PhD (Pfizer), and Tamar Thompson (Alexion Pharmaceuticals, Inc.) will discuss the future of drug development and personalized medicine. Today, PMC sets the stage, here: https://bit.ly/3PAADFt

The pharmaceutical landscape in the US is witnessing its most significant transformation in two decades with the implementation of the Inflation Reduction Act (#IRA), ushering in a new era of drug price regulation. A core pillar of the IRA is the negotiation of prices on certain high-spend drugs, as well as Medicare Part D redesign. Especially the implications of the IRA and the US healthcare system’s transitions toward regulated drug pricing are vast and complex. First and foremost, pharmaceutical companies must adapt to the new negotiating landscape and reconsider their strategies. 💡 Dive into our study, which showcases the pivotal IRA provisions and the implications for pharmaceutical companies and patients: ➡ https://lnkd.in/dc5Metzr #RolandBerger Filip Conic